<DOC>
	<DOCNO>NCT02623699</DOCNO>
	<brief_summary>The primary objective study evaluate safety , tolerability , pharmacokinetics ( PK ) BIIB067 adults ALS . The secondary objective evaluate effect BIIB067 level superoxide dismutase 1 ( SOD1 ) protein cerebrospinal fluid ( CSF ) .</brief_summary>
	<brief_title>Single Multiple Dose Study BIIB067 Adults With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Key Weakness attributable ALS document SOD1 mutation Screening Visit 2 . A forced vital capacity ( FVC ) ≥50 % predict value adjust sex , age , height ( sit position ) . Participants stable FVC &lt; 50 % ≥45 % , whose FVC decline 5 % last 6 month may consider inclusion , discretion Investigator . If taking riluzole , Participant must stable dose ≥30 day prior Day 1 expect remain dose final study visit . Medically able undergo study procedure , adhere visit schedule time study entry , determine Investigator . Key History positive test result human immunodeficiency virus . History positive test result hepatitis C virus antibody hepatitis B virus ( define positive hepatitis B surface antigen hepatitis B core antibody ) . Treatment another investigational drug , biological agent , device within 1 month 5 halflives study agent , whichever longer . Specifically , prior treatment small interfering ribonucleic acid , stem cell therapy , gene therapy allow . Current enrollment interventional study . Current recent ( within 1 month ) use , anticipate need , opinion Investigator , copper ( II ) ( diacetylbis ( N4methylthiosemicarbazone ) ) pyrimethamine . Current anticipate need , opinion Investigator , diaphragm pacing system ( DPS ) study period . Tracheostomy NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Isis-SOD1Rx</keyword>
	<keyword>SOD1</keyword>
	<keyword>ALS</keyword>
</DOC>